Core Insights - Polyrizon Ltd. has initiated preliminary work on the GMP manufacturing process for its PL-14 allergy blocker, preparing for a clinical trial planned for 2025 [1][2] - The collaboration with Eurofins CDMO Amatsiaquitaine S.A.S. aims to ensure high-quality production and compliance with regulatory standards for the clinical trial material [2][3] - The global nasal spray market is projected to exceed $23 billion by 2029, indicating significant growth potential for innovative solutions like Polyrizon's PL-14 [3] Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask," providing a thin shield in the nasal cavity [4] - The company is also developing the Trap and Target ™ technology for nasal delivery of active pharmaceutical ingredients, currently in pre-clinical development [4] Industry Context - Eurofins CDMO is a prominent Contract Development & Manufacturing Organization (CDMO) that provides comprehensive outsourcing services for preclinical and clinical phases, specializing in both Drug Substance/API and Drug Product development [5]
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial